Acute Promyelocytic Leukemia: Review of Complications Related to All-Trans Retinoic Acid and Arsenic Trioxide Therapy

• Published in: Cancers 2024-03, Vol.16 (6), p.1160
• Main Authors: Ghiaur, Alexandra, Doran, Cristina, Gaman, Mihnea-Alexandru, Ionescu, Bogdan, Tatic, Aurelia, Cirstea, Mihaela, Stancioaica, Maria Camelia, Hirjan, Roxana, Coriu, Daniel
• Format: Article
• Language: English
• Subjects: Acute promyeloid leukemia; Adverse events; Apoptosis; Arsenic; Arsenic trioxide; Cancer; Chemotherapy; Clinical trials; Comorbidity; Complications and side effects; Drug dosages; FDA approval; Leukemia; Liver; Middle Ages; Mortality; Neurotoxicity; Patients; Posaconazole; Promyeloid leukemia; Remission; Remission (Medicine); Review; Toxicity
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers16061160

The hallmark of acute promyelocytic leukemia (APL) is the presence of the characteristic fusion transcript of the promyelocytic leukemia gene with the retinoic acid receptor α gene (PML::RARA). The PML::RARA fusion is a molecular target for all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). Therapies based on ATRA plus ATO have excellent outcomes in terms of complete remission rates, overall survival, and achievement of deep and durable molecular responses with a very low incidence of relapse. However, although the combination of ATRA and ATO has lower hematologic toxicity than standard chemotherapy, its use is associated with a spectrum of distinctive toxicities, such as differentiation syndrome, liver toxicity, QT interval prolongation, and neurotoxicity. Rigorous monitoring of patients' clinical evolution is indispensable for identifying and addressing each complication. The objective is to maintain an equilibrium between treatment-induced adverse events and therapeutic efficacy. This paper focused on non-hematologic complications associated with the combination of ATRA and ATO. Additionally, we discuss late-onset complications of this therapy. In summary, the majority of treatment-related adverse events are manageable, self-limiting, and reversible. More so, there seems to be a lower incidence rate of secondary neoplasms compared to standard chemotherapy. However, further research is required to assess how the ATRA plus ATO regimen affects the emergence of additional comorbidities.